About
Dale Pfost joined Advent in 2010. He has more than 25 years of experience as a life science entrepreneur and executive, with expertise in high technology research tools, genomics, diagnostics and therapeutics. Dale's first company, founded while he was in graduate school, was acquired by SmithKline Beckman. He was founding CEO and Chairman of Orchid BioSciences, a pioneer in genetic analysis and personalized medicine that Dale and his team built through strategic acquisitions and took public in 2000 (NASDAQ: ORCH). Dale then became founding CEO and Chairman of Acuity Pharmaceuticals, an innovative ophthalmology company that was acquired by OPKO Health (NYSE AMEX: OPK). As CEO of cancer drug developer Receptor BioLogix, Dale readied the company for a successful acquisition by a European biotechnology firm. Earlier in his career, he was co-founder and CEO of Advent-backed Oxford GlycoSciences (IPO on NASDAQ and LSE).
Position in the VCSift Database
- • 12 investors at Advent Life Sciences are tracked.
- • 626 investors hold the General Partner role in VCSift. Dale Pfost is one of them.
- • 1,751 investors are based in California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- California, US
Contact Information
Find more investors like Dale
Search Investors